Arcturus Therapeutics Holdings Inc. (ARCT) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Overview
As of November 8, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) reported trailing twelve-month net income of -$78M, reflecting +20.0% year-over-year growth. The company earned $-2.74 per diluted share over the past four quarters, with a net profit margin of -97.9%.
Looking at the long-term picture, ARCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2022.
Arcturus Therapeutics Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$2.79B net income, -145.2% margin), BNTX (-$1.48B net income, -39.6% margin), NTLA (-$426M net income, -609.9% margin), ARCT has outperformed on profitability metrics. Compare ARCT vs MRNA →
ARCT Earnings vs Peers
Earnings metrics vs comparable public companies
ARCT Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$66M | +18.7% | -$75M | $-2.40 | -97.9% | -111.5% |
| 2024 | -$81M | -172.3% | -$96M | $-3.00 | -58.5% | -69.1% |
| 2023 | -$30M | -417.9% | -$78M | $-1.12 | -18.8% | -49.6% |
| 2022 | $9M | +104.6% | $12M | $0.35 | 4.5% | 5.9% |
| 2021 | -$204M | -182.3% | -$203M | $-7.74 | -1648.0% | -1641.3% |
| 2020 | -$72M | -177.6% | -$72M | $-3.55 | -756.3% | -749.8% |
| 2019 | -$26M | -19.3% | -$26M | $-2.13 | -125.0% | -122.7% |
| 2018 | -$22M | -99.8% | -$22M | $-2.16 | -138.3% | -138.5% |
| 2017 | -$11M | +55.7% | -$10M | $-3.53 | -83.9% | -80.7% |
| 2016 | -$25M | -26.5% | -$25M | $-6.25 | -120.7% | -123.5% |
| 2015 | -$19M | +40.8% | -$20M | $-6.29 | -316.9% | -320.9% |
| 2014 | -$33M | -211.3% | -$33M | $-16.81 | - | - |
| 2013 | -$11M | -568.0% | -$10M | $-7.25 | - | - |
| 2012 | -$2M | +59.8% | -$2M | $-0.99 | - | - |
| 2011 | -$4M | - | -$4M | $-2.47 | - | - |
Download Data
Export ARCT earnings history in CSV or JSON format
Free sign-in required to download data
ARCT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARCT — Frequently Asked Questions
Quick answers to the most common questions about buying ARCT stock.
What is ARCT earnings per share (EPS)?
ARCT trailing twelve-month (TTM) diluted EPS is $-2.74, reflecting +20.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Arcturus Therapeutics Holdings Inc.'s net income?
Arcturus Therapeutics Holdings Inc. (ARCT) trailing twelve-month net income is $-78M as of 2025. Earnings grew +20.0% year-over-year.
Is ARCT profitable?
ARCT is not currently profitable on a TTM basis, reporting a net loss of $-78M. Net margin is -97.9%. Investors should monitor for a return to profitability.
What is ARCT's earnings growth rate?
ARCT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are ARCT's profit margins?
Arcturus Therapeutics Holdings Inc. net profit margin is -97.9%, operating margin is -111.5%, and gross margin is +95.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -28.9%.
Is ARCT growing earnings?
Yes, ARCT earnings are accelerating — EPS growth of +20.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-78M. Earnings momentum is strengthening.
What was ARCT's best earnings year?
Arcturus Therapeutics Holdings Inc.'s highest annual net income on record is $9M, achieved in fiscal year 2022. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were ARCT's earnings last quarter?
ARCT's most recent reported quarter was Q3 2026. Net income was $2M with diluted EPS of $-0.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.